论文部分内容阅读
目的探究为慢阻肺病人使用特布他林与糖皮质激素配合治疗的临床效果。方法在治疗的慢阻肺病人中选取66例作为研究对象,将其分为研究组(33例)与对照组(33例)。给予对照组特布他林治疗,研究组在对照组基础上加用糖皮质激素治疗,比较分析两组病人的治疗效果,以及肺功能指标的变化情况。结果治疗前,PEF、FEV1预计值、FEV1/FEV肺功能指标组间对比,差异不明显(P>0.05)。治疗后,研究组病人的治疗总有效率(93.94%)高于对照组病人(75.76%);PEF、FEV1预计值、FEV1/FEV肺功能指标改善程度,均大于对照组病人,差异均显著(P<0.05)。结论为慢阻肺病人使用特布他林与糖皮质激素类药物配合治疗,可有效改善病人PEF、FEV1预计值、FEV1/FEV肺功能指标水平,是较佳的治疗方法。
Objective To investigate the clinical effects of terbutaline and glucocorticoid in the treatment of COPD patients. Methods Sixty-six patients with COPD were selected as study group and divided into study group (33 cases) and control group (33 cases). The control group was treated with terbutaline. The study group was treated with glucocorticoid on the basis of the control group. The therapeutic effect of the two groups of patients and the change of pulmonary function indexes were compared. Results Before treatment, PEF, FEV1 predicted value, FEV1 / FEV pulmonary function indicators between the two groups showed no significant difference (P> 0.05). After treatment, the total effective rate (93.94%) in the study group was higher than that in the control group (75.76%). The predictive value of PEF, FEV1 and the improvement of pulmonary function of FEV1 / FEV were significantly higher than those in the control group P <0.05). Conclusions: The combination of terbutaline and glucocorticoids in COPD patients can effectively improve the predictive value of PEF, FEV1 and the pulmonary function indexes of FEV1 / FEV in patients with COPD, which is a better treatment.